Skip to main content

Professional cross-priming for ovary and prostate cancer

Objective

Immune responses are initiated by antigen presentation mediated by dendritic cells (DC). There is a minority subset of DC highly specialised in starting up cytotoxic T lymphocytes able to kill tumor cells. PROCROP aims to develop in three pilot clinical trials a suitable individualized cancer vaccine technology for castration resistant prostate cancer and metastatic cancer of the ovary that would complement currently available therapies to increase efficacy. The project applies recent compelling knowledge on the identity of the main antigen-presenting DC subsets for vaccine elicitation of cytotoxic T lymphocytes endowed with the ability to seek and destroy tumour cells (such immune mechanism is termed crosspriming). This unique opportunity for superior DCs for immunotherapy comes from the fact that Miltenyi, a successful European biotech company, has the necessary proprietary reagents (anti-BDCA-3 monoclonal antibody and immunomagnetic selection technology), as well as the expertise to clinically develop a strategy of DC isolation and short-term cell culture for immunotherapy. From the point of view of the tumor antigens, processed autologous tumor material will be mixed with defined common tumor antigens in the form of recombinant proteins. This novel combination will permit stronger and broader antitumor immune responses and more accurate monitoring of the ensuing immunity against the tumors. These features should make the novel DC vaccine more efficacious than the currently US-approved DC vaccine PROVENGE and other DCs preparations undergoing trials, such as those derived from monocytes. Three of the leading groups in immunotherapy of cancer in Europe would join forces to develop this individualized cell therapy technology in clinical trials for two highly prevalent and unsatisfactorily managed malignant conditions. Industrial partnership provides the unique advantage of producing a rigorously standardized product for eventual multicentre trials.

Field of science

  • /medical and health sciences/health sciences/public and environmental health/epidemics prevention/immunisation
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug/vaccines
  • /medical and health sciences/clinical medicine/cancer/prostate cancer
  • /medical and health sciences/basic medicine/immunology/immunotherapy
  • /medical and health sciences/medical biotechnology/cells technologies

Call for proposal

H2020-PHC-2014-two-stage
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA
Address
Avenida De Pio Xii 55
31008 Pamplona
Spain
Activity type
Research Organisations
EU contribution
€ 1 190 000

Participants (6)

STICHTING KATHOLIEKE UNIVERSITEIT
Netherlands
EU contribution
€ 1 510 000
Address
Geert Grooteplein Noord 9
6525 EZ Nijmegen
Activity type
Higher or Secondary Education Establishments
MILTENYI BIOTEC GMBH
Germany
EU contribution
€ 1 345 000
Address
Friedrich Ebert Strasse 68
51429 Bergish Gladbach
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)
Spain
EU contribution
€ 655 000
Address
Calle Melchor Fernandez Almagro 3
28029 Madrid
Activity type
Research Organisations
UNIVERSIDAD DE NAVARRA
Spain
EU contribution
€ 1 050 000
Address
Campus Universitario Edificio Central
31080 Pamplona
Activity type
Higher or Secondary Education Establishments
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS
Switzerland
EU contribution
€ 0
Address
Rue Du Bugnon 21
1011 Lausanne
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
UNIVERSITE DE LAUSANNE
Switzerland
EU contribution
€ 0
Address
Quartier Unil-centre Bâtiment Unicentre
1015 Lausanne
Activity type
Higher or Secondary Education Establishments